COVID-19 in patients with classic and variant hairy cell leukemia
Robert J. Kreitman(National Cancer Institute), Evgeny Arons(National Institutes of Health), Constance M. Yuan(National Cancer Institute), Jeffrey I. Cohen(National Institutes of Health), Holly Eager(National Institutes of Health), Peter D. Burbelo(National Institutes of Health), Julie Feurtado(National Institutes of Health), Jack Mauter(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Hong Zhou(National Institutes of Health), M N Gould(National Institutes of Health), Olena Sierra Ortiz(National Institutes of Health), Theresa Yu(University of California, San Francisco), Lacey James(National Institutes of Health)
Cited by 5
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
|JAMA Oncology|2015|309
Immunotoxins for targeted cancer therapy
|The AAPS Journal|2006|307